Background In 2013, denosumab was introduced as peri-operative adjuvant treatment for
giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that …

Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated
with a large biological spectrum ranging from latent benign to highly recurrent and …

Giant cell tumor of the bone (GCTB) is a locally aggressive tumor with a certain distant
metastatic rate. For sacral GCT (SGCT) and pelvic GCT (PGCT), surgery has its limitations …

Study Design. A prospective cohort study. Objective. The aim of this study was to evaluate
the interest of denosumab in the treatment of spinal giant-cells tumors (GCTs) and …

A nonrandomized controlled study of sacral giant cell tumors... : Medicine A nonrandomized
controlled study of sacral giant cell tumors with preoperative treatment of denosumab : Medicine …

Background Giant cell tumours (GCT) of bone are benign neoplasms associated with a high
rate of local recurrence after extensive intra-lesional curettage. Recently, understanding of …

OBJECT There is no consensus regarding the appropriate treatment of sacral giant cell
tumor (GCT). There are 3 main management problems: tumor control, neurological loss, and …

Simple Summary Giant cell tumours are benign but locally aggressive and can potentially
metastasise to the lungs. Reducing the risk of local recurrence while maintaining limb …

Purpose Giant cell tumors of sacrum in which surgery could endanger important neural
components were treated with short term denosumab, angioembolisation and radiotherapy …

Background The purpose of this study is to analyze the overall prognosis of giant cell tumor
of bone (GCTB) and the risk factors that affect its postoperative recurrence. Methods The …